Dear colleagues, I'll call us back to order.
We're so pleased to welcome a new set of witnesses.
I would like to make a few comments for the benefit of the new witnesses.
Please wait until I recognize you by name before speaking. For those participating by videoconference, click on the microphone icon to activate your mike and please mute yourself when you are not speaking.
Regarding interpretation for those on Zoom—you have the choice, at the bottom of your screen, of either Floor, English or French. For those in the room, you can use the earpiece and select the desired channel.
I would now like to welcome our witnesses.
As an individual, we have Dr. Guy Rouleau, director of the Montreal Neurological Institute and Hospital.
Welcome. We're delighted to have you.
From BioCanRx, we have Dr. Stéphanie Michaud, president and chief executive officer, and Dr. John Bell, scientific director. Welcome to you both.
Coming back to us again, we're so pleased to have Joseph McBrearty, president and chief executive officer of Canadian Nuclear Laboratories.
I'd like to welcome all the witnesses. Each group will have five minutes to present. At the four-and-a-half-minute mark, I will hold up a yellow card to let you know that you have 30 seconds left and I hope you'll wrap up. We aim to be fair.
With that, let's start with Dr. Rouleau. The floor is yours for five minutes.